<DOC>
	<DOCNO>NCT00094380</DOCNO>
	<brief_summary>The purpose study examine safety single dose RG2077 patient systemic lupus erythematosus ( SLE ) currently receive cyclophosphamide . This study also determine RG2077 effective decrease disease activity patient . Study hypothesis : CTLA4-Ig mediates T cell costimulatory blockade effectively induce antigen-specific nonresponsiveness T cell .</brief_summary>
	<brief_title>Treating Systemic Lupus Erythematosus ( SLE ) Patients With CTLA4-IgG4m ( RG2077 )</brief_title>
	<detailed_description>SLE chronic , inflammatory autoimmune disorder may affect many organ system , include skin , joint , internal organ . RG2077 study use multiple sclerosis , another autoimmune disorder . This study evaluate safety efficacy RG2077 SLE patient currently receive cyclophosphamide . This trial compose two part . The first part dose-escalation study participant receive one two dos RG2077 ( 0.2 mg/kg 2 mg/kg ) ; part study last 60 day . At screening , patient IV catheter insert arm administration cyclophosphamide RG2077 . Patients also medical medication history assessment , comprehensive physical exam , blood urine test . There 5 study visit first part trial ; occur screening , study entry , Days 1 , 14 , 28 . Selected visit include physical exam , vital sign measurement , blood urine test , disease activity assessment . At Days 7 60 , patient contact phone report medication history adverse effect experience . The second part study evaluate single 10 mg/kg dose RG2077 ; part study last 90 day . In study , participant randomly assign one two group . At start study , Group 1 participant receive RG2077 cyclophosphamide Group 2 participant receive cyclophosphamide . There 9 study visit ; occur study screen , study entry , Days 1 , 4 , 7 , 14 , 28 , 60 . At select visit , patient undergo physical exam , vital sign measurement , blood test urine test , disease activity assessment .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Diagnosis SLE American College Rheumatology ( ACR ) criteria Concurrent treatment intravenous cyclophosphamide ( 500 1000 mg/m2 ) least one follow manifestation lupus : World Health Organization ( WHO ) class III , IV , V lupus nephritis ; British Isles Lupus Assessment Group ( BILAG ) score A vasculitis ; BILAG score A cytopenia ; BILAG score A nervous system Stable medication regimen least 4 week prior study entry Weight 40 kg ( 88.2 lb ) 125 kg ( 275.6 lb ) Willing use acceptable form contraception Moderately severe anemia ( hemoglobin le 8 mg/dL ) Neutropenia ( absolute neutrophil count le 1,500/mm3 ) Thrombocytopenia ( platelet le 50,000/mm3 ) Positive tuberculin ( PPD ) test without evidence prior treatment administration bacille CalmetteGu√©rin ( BCG ) vaccine Active infection , include HIV hepatitis B C Receipt live vaccine within 3 month study entry Endstage renal disease creatinine clearance le 20 ml/min/1.73 m2 History cancer . Patients history carcinoma situ treat basal squamous cell carcinoma exclude . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Lupus Nephritis</keyword>
</DOC>